A Phase III Clinical Study on the Efficacy and Safety of STSP-0601 for Injection in Patients With Hemophilia Associated With Inhibitors, With a Multicenter, Open Evaluation Approach
Latest Information Update: 22 May 2026
At a glance
- Drugs STSP-0601 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu BioJeTay Biotechnology
Most Recent Events
- 23 Apr 2026 Planned number of patients changed from 32 to 40.
- 23 Apr 2026 Planned End Date changed from 1 Dec 2026 to 1 Mar 2027.
- 16 Apr 2025 New trial record